BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol 2019;4:206-13. [PMID: 30758506 DOI: 10.1001/jamacardio.2018.4936] [Cited by in Crossref: 81] [Cited by in F6Publishing: 68] [Article Influence: 40.5] [Reference Citation Analysis]
Number Citing Articles
1 Underberg J, Toth PP, Rodriguez F. LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals. Postgrad Med 2022. [PMID: 36004573 DOI: 10.1080/00325481.2022.2117498] [Reference Citation Analysis]
2 Golder S, Weissenbacher D, O’connor K, Hennessy S, Gross R, Hernandez GG. Patient-Reported Reasons for Switching or Discontinuing Statin Therapy: A Mixed Methods Study Using Social Media. Drug Saf. [DOI: 10.1007/s40264-022-01212-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sampson M, Wolska A, Amar M, Ueda M, Dunbar R, Soffer D, Remaley AT. Estimated Atherosclerotic Cardiovascular Disease Risk Score: An Automated Decision Aid for Statin Therapy. Clin Chem 2022:hvac120. [PMID: 35900196 DOI: 10.1093/clinchem/hvac120] [Reference Citation Analysis]
4 Patnaik S, Pollevick ME, Lara-Breitinger KM, Stone NJ, Patnaik S, Pollevick ME, Lara-Breitinger KM, Stone NJ. Inter-Individual Variability in Lipid Response: A Narrative Review. Am J Med 2022:S0002-9343(22)00529-0. [PMID: 35878687 DOI: 10.1016/j.amjmed.2022.06.018] [Reference Citation Analysis]
5 Devareddy A, Sarraju A, Rodriguez F. Health Disparities Across the Continuum of ASCVD Risk. Curr Cardiol Rep 2022. [PMID: 35788894 DOI: 10.1007/s11886-022-01736-y] [Reference Citation Analysis]
6 Gao C, Liu C, Chen Q, Wang Y, Kwong CHT, Wang Q, Xie B, Lee SMY, Wang R. Cyclodextrin-mediated conjugation of macrophage and liposomes for treatment of atherosclerosis. J Control Release 2022:S0168-3659(22)00395-9. [PMID: 35779655 DOI: 10.1016/j.jconrel.2022.06.053] [Reference Citation Analysis]
7 Ala M, Eftekhar SP. The Footprint of Kynurenine Pathway in Cardiovascular Diseases. Int J�Tryptophan�Res 2022;15:117864692210966. [DOI: 10.1177/11786469221096643] [Reference Citation Analysis]
8 Soffer D, Stoekenbroek R, Plakogiannis R. Small interfering ribonucleic acid for cholesterol lowering – Inclisiran. Journal of Clinical Lipidology 2022. [DOI: 10.1016/j.jacl.2022.06.009] [Reference Citation Analysis]
9 Zhou YF, Wang Y, Wang G, Zhou Z, Chen S, Geng T, Zhang YB, Wang Y, Chen JX, Pan A, Wu S. Association Between Statin Use and Progression of Arterial Stiffness Among Adults With High Atherosclerotic Risk. JAMA Netw Open 2022;5:e2218323. [PMID: 35713899 DOI: 10.1001/jamanetworkopen.2022.18323] [Reference Citation Analysis]
10 Khan Minhas AM, Ijaz SH, Javed N, Sheikh AB, Jain V, Michos ED, Greene SJ, Fudim M, Warraich HJ, Shapiro MD, Al-Kindi SG, Sperling L, Virani SS. National Trends and Disparities in Statin Use for Ischemic Heart Disease from 2006 to 2018: Insights from National Ambulatory Medical Care Survey. Am Heart J 2022:S0002-8703(22)00109-0. [PMID: 35644222 DOI: 10.1016/j.ahj.2022.05.015] [Reference Citation Analysis]
11 Chang RW, Tucker LY, Rothenberg KA, Lancaster E, Faruqi RM, Kuang HC, Flint AC, Avins AL, Nguyen-Huynh MN. Incidence of Ischemic Stroke in Patients With Asymptomatic Severe Carotid Stenosis Without Surgical Intervention. JAMA 2022;327:1974-82. [PMID: 35608581 DOI: 10.1001/jama.2022.4835] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Macchi C, Bonalume V, Greco MF, Mozzo M, Melfi V, Sirtori CR, Magnaghi V, Corsini A, Ruscica M. Impact of Atorvastatin on Skeletal Muscle Mitochondrial Activity, Locomotion and Axonal Excitability-Evidence from ApoE-/- Mice. Int J Mol Sci 2022;23:5415. [PMID: 35628225 DOI: 10.3390/ijms23105415] [Reference Citation Analysis]
13 Maitra NS, Mahtta D, Navaneethan S, Vaughan EM, Kochar A, Gulati M, Levine GN, Petersen LA, Virani SS. A Mistake Not to Be Repeated: What Can We Learn from the Underutilization of Statin Therapy for Efficient Dissemination of Cardioprotective Glucose Lowering Agents? Curr Cardiol Rep 2022. [PMID: 35352278 DOI: 10.1007/s11886-022-01694-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Ferraro RA, Leucker T, Martin SS, Banach M, Jones SR, Toth PP. Contemporary Management of Dyslipidemia. Drugs 2022. [PMID: 35303294 DOI: 10.1007/s40265-022-01691-6] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Zhao D, Liu Y, Chen S, Xu Z, Yang X, Shen H, Zhang S, Li Y, Zhang H, Zou C, Ma X. Predictive Value of Blood Urea Nitrogen to Albumin Ratio in Long-Term Mortality in Intensive Care Unit Patients with Acute Myocardial Infarction: A Propensity Score Matching Analysis. IJGM 2022;Volume 15:2247-59. [DOI: 10.2147/ijgm.s349722] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Chi CL, Wang J, Ying Yew P, Lenskaia T, Loth M, Mani Pradhan P, Liang Y, Kurella P, Mehta R, Robinson JG, Tonellato PJ, Adam TJ. Producing personalized statin treatment plans to optimize clinical outcomes using big data and machine learning. J Biomed Inform 2022;:104029. [PMID: 35182785 DOI: 10.1016/j.jbi.2022.104029] [Reference Citation Analysis]
17 Katzmann JL, Cupido AJ, Laufs U. Gene Therapy Targeting PCSK9. Metabolites 2022;12:70. [PMID: 35050192 DOI: 10.3390/metabo12010070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
18 Banach M, Burchardt P, Chlebus K, Dobrowolski P, Dudek D, Dyrbuś K, Gąsior M, Jankowski P, Jóźwiak J, Kłosiewicz-Latoszek L, Kowalska I, Małecki M, Prejbisz A, Rakowski M, Rysz J, Solnica B, Sitkiewicz D, Sygitowicz G, Sypniewska G, Tomasik T, Windak A, Zozulińska-Ziółkiewicz D, Cybulska B. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci 2021;17:1447-547. [PMID: 34900032 DOI: 10.5114/aoms/141941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Alefan Q, Yao S, Taylor JG, Lix LM, Eurich D, Choudhry N, Blackburn DF. Factors associated with early nonpersistence among patients experiencing side effects from a new medication. J Am Pharm Assoc (2003) 2021:S1544-3191(21)00546-X. [PMID: 34980560 DOI: 10.1016/j.japh.2021.12.001] [Reference Citation Analysis]
20 Umarje S, James NM, Dave P, Raut A, Pandey N. Impact of Adherence, Patient Perception, and Knowledge to Statin Therapy - A Cross-Sectional Study. Indian J Endocrinol Metab 2021;25:206-10. [PMID: 34760675 DOI: 10.4103/ijem.ijem_120_21] [Reference Citation Analysis]
21 Shang C, Lin H, Fang X, Wang Y, Jiang Z, Qu Y, Xiang M, Shen Z, Xin L, Lu Y, Gao J, Cui X. Beneficial effects of cinnamon and its extracts in the management of cardiovascular diseases and diabetes. Food Funct 2021. [PMID: 34752593 DOI: 10.1039/d1fo01935j] [Reference Citation Analysis]
22 Dephillips C, Parikh PB, Stevens GA. Dyslipidemia: Current Therapies and Strategies to Overcome Barriers for Use. The Journal for Nurse Practitioners 2021;17:1167-73. [DOI: 10.1016/j.nurpra.2021.08.012] [Reference Citation Analysis]
23 Bai L, Scott MKD, Steinberg E, Kalesinskas L, Habtezion A, Shah NH, Khatri P. Computational drug repositioning of atorvastatin for ulcerative colitis. J Am Med Inform Assoc 2021;28:2325-35. [PMID: 34529084 DOI: 10.1093/jamia/ocab165] [Reference Citation Analysis]
24 Kristiansen O, Sverre E, Peersen K, Fagerland MW, Gjertsen E, Gullestad L, Perk J, Dammen T, Husebye E, Vethe NT, Munkhaugen J. The relationship between directly measured statin adherence, self-reported adherence measures and cholesterol levels in patients with coronary heart disease. Atherosclerosis 2021;336:23-9. [PMID: 34610521 DOI: 10.1016/j.atherosclerosis.2021.09.020] [Reference Citation Analysis]
25 Jia X, Lee MT, Ramsey DJ, Mahtta D, Akeroyd JM, Turchin A, Navar AM, Matheny ME, Gobbel G, Stone NJ, Nambi V, Ballantyne CM, Petersen LA, Virani SS. Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the veteran's affairs healthcare system. J Clin Lipidol 2021:S1933-2874(21)00249-X. [PMID: 34666951 DOI: 10.1016/j.jacl.2021.09.050] [Reference Citation Analysis]
26 Toth PP. That Myalgia of Yours Is Not From Statin Intolerance. J Am Coll Cardiol 2021;78:1223-6. [PMID: 34531022 DOI: 10.1016/j.jacc.2021.07.025] [Reference Citation Analysis]
27 Grundy SM, Stone NJ, Blumenthal RS, Braun LT, Heidenreich PA, Lloyd-Jones D, Orringer CE, Saseen JJ, Smith SC Jr, Sperling LS, Virani SS. High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. Mayo Clin Proc 2021;96:2660-70. [PMID: 34531060 DOI: 10.1016/j.mayocp.2021.02.032] [Reference Citation Analysis]
28 Araújo PM, Nunes A, Torres S, Resende CX, Leite SM, Rodrigues JD, Amorim S, Martins E, Campelo M, Maciel MJ. Temporal trends of lipid control in very high cardiovascular risk patients. Rev Port Cardiol (Engl Ed) 2021;40:641-8. [PMID: 34503701 DOI: 10.1016/j.repce.2020.10.021] [Reference Citation Analysis]
29 Carnicelli AP, Li Z, Greiner MA, Lippmann SJ, Greene SJ, Mentz RJ, Hardy NC, Blumer V, Shen X, Yancy CW, Peterson PN, Allen LA, Fonarow GC, O'Brien EC. Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. JACC Heart Fail 2021:S2213-1779(21)00335-8. [PMID: 34509408 DOI: 10.1016/j.jchf.2021.06.018] [Reference Citation Analysis]
30 Pinsky P, Goodman P, Parnes H, Ford L, Minasian L. Adherence with protocol medication use and mortality from unrelated causes in a prevention trial. Prev Med 2021;153:106778. [PMID: 34450188 DOI: 10.1016/j.ypmed.2021.106778] [Reference Citation Analysis]
31 Al Rifai M, Blumenthal RS, Stone NJ, Schofield RS, Orringer CE, Michos ED, Heidenreich PA, Braun L, Birtcher KK, Smith SC, Nambi V, Grundy S, Virani SS. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context. Prog Cardiovasc Dis 2021:S0033-0620(21)00089-X. [PMID: 34371083 DOI: 10.1016/j.pcad.2021.08.001] [Reference Citation Analysis]
32 Östbring MJ, Eriksson T, Petersson G, Hellström L. Effects of a pharmaceutical care intervention on clinical outcomes and patient adherence in coronary heart disease: the MIMeRiC randomized controlled trial. BMC Cardiovasc Disord 2021;21:367. [PMID: 34334142 DOI: 10.1186/s12872-021-02178-0] [Reference Citation Analysis]
33 Toth PP. Low-Density Lipoprotein Cholesterol Treatment Rates in High Risk Patients: More Disappointment Despite Ever More Refined Evidence-Based Guidelines. Am J Prev Cardiol 2021;6:100186. [PMID: 34327506 DOI: 10.1016/j.ajpc.2021.100186] [Reference Citation Analysis]
34 Solmi M, Tiihonen J, Lähteenvuo M, Tanskanen A, Correll CU, Taipale H. Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study. Schizophr Bull 2021:sbab087. [PMID: 34286338 DOI: 10.1093/schbul/sbab087] [Reference Citation Analysis]
35 Deshotels MR, Virani SS, Ballantyne CM. Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures? Curr Cardiol Rep 2021;23:116. [PMID: 34269897 DOI: 10.1007/s11886-021-01545-9] [Reference Citation Analysis]
36 Mark L, Reiber I, Toth PP. Statin Prescribing and Dosing-Failure Has Become an Option. JAMA Cardiol 2021;6:854-5. [PMID: 33909025 DOI: 10.1001/jamacardio.2021.0832] [Reference Citation Analysis]
37 Brunette CA, Vassy JL. The role of SLCO1B1 genotyping in lowering cardiovascular risk. Pharmacogenomics 2021;22:649-56. [PMID: 34196599 DOI: 10.2217/pgs-2021-0075] [Reference Citation Analysis]
38 Araújo PM, Nunes A, Torres S, Resende CX, Leite SM, Rodrigues JD, Amorim S, Martins E, Campelo M, Maciel MJ. Temporal trends of lipid control in very high cardiovascular risk patients. Rev Port Cardiol 2021;40:641-8. [PMID: 34112555 DOI: 10.1016/j.repc.2020.10.018] [Reference Citation Analysis]
39 Peterson GG, Pu J, Magid DJ, Barterian L, Kranker K, Barna M, Conwell L, Rose A, Blue L, Markovitz A, McCall N, Markovich P. Effect of the Million Hearts Cardiovascular Disease Risk Reduction Model on Initiating and Intensifying Medications: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol 2021. [PMID: 34076665 DOI: 10.1001/jamacardio.2021.1565] [Reference Citation Analysis]
40 Dungan JR, Qin X, Hurdle M, Haynes CS, Hauser ER, Kraus WE. Genome-Wide Variants Associated With Longitudinal Survival Outcomes Among Individuals With Coronary Artery Disease. Front Genet 2021;12:661497. [PMID: 34140969 DOI: 10.3389/fgene.2021.661497] [Reference Citation Analysis]
41 Bona K, Brazauskas R, He N, Lehmann L, Abdel-Azim H, Ahmed IA, Al-Homsi AS, Aljurf M, Arnold SD, Badawy SM, Battiwalla M, Beattie S, Bhatt NS, Dalal J, Dandoy CE, Diaz MA, Frangoul HA, Freytes CO, Ganguly S, George B, Gomez-Almaguer D, Hahn T, Kamble RT, Knight JM, LeMaistre CF, Law J, Lazarus HM, Majhail NS, Olsson RF, Preussler J, Savani BN, Schears R, Seo S, Sharma A, Srivastava A, Steinberg A, Szwajcer D, Wirk B, Yoshimi A, Khera N, Wood WA, Hashmi S, Duncan CN, Saber W. Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. Blood 2021;137:556-68. [PMID: 33104215 DOI: 10.1182/blood.2020006252] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
42 Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, DeNizio JE, Reiss CW, Wang K, Iyer S, Dutta C, Clendaniel V, Amaonye M, Beach A, Berth K, Biswas S, Braun MC, Chen HM, Colace TV, Ganey JD, Gangopadhyay SA, Garrity R, Kasiewicz LN, Lavoie J, Madsen JA, Matsumoto Y, Mazzola AM, Nasrullah YS, Nneji J, Ren H, Sanjeev A, Shay M, Stahley MR, Fan SHY, Tam YK, Gaudelli NM, Ciaramella G, Stolz LE, Malyala P, Cheng CJ, Rajeev KG, Rohde E, Bellinger AM, Kathiresan S. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 2021;593:429-34. [PMID: 34012082 DOI: 10.1038/s41586-021-03534-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 21.0] [Reference Citation Analysis]
43 Sinnaeve PR, Schwartz GG, Wojdyla DM, Alings M, Bhatt DL, Bittner VA, Chiang CE, Correa Flores RM, Diaz R, Dorobantu M, Goodman SG, Jukema JW, Kim YU, Pordy R, Roe MT, Sy RG, Szarek M, White HD, Zeiher AM, Steg PG; ODYSSEY OUTCOMES Investigators. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis.Eur Heart J. 2020;41:2248-2258. [PMID: 31732742 DOI: 10.1093/eurheartj/ehz809] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 18.0] [Reference Citation Analysis]
44 Carmona A, Marchandot B, Matsushita K, Morel O. Letter by Carmona et al Regarding Article, "Beneficial Effect of Statins in COVID-19-Related Outcomes-Brief Report: a National Population-Based Cohort Study". Arterioscler Thromb Vasc Biol 2021;41:e280-1. [PMID: 33881925 DOI: 10.1161/ATVBAHA.121.316224] [Reference Citation Analysis]
45 Jones LK, Tilberry S, Gregor C, Yaeger LH, Hu Y, Sturm AC, Seaton TL, Waltz TJ, Rahm AK, Goldberg A, Brownson RC, Gidding SS, Williams MS, Gionfriddo MR. Implementation strategies to improve statin utilization in individuals with hypercholesterolemia: a systematic review and meta-analysis. Implement Sci 2021;16:40. [PMID: 33849601 DOI: 10.1186/s13012-021-01108-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Ryou IS, Chang J, Son JS, Ko A, Choi S, Kim K, Kim SM, Park SM. Association between CVDs and initiation and adherence to statin treatment in patients with newly diagnosed hypercholesterolaemia: a retrospective cohort study. BMJ Open 2021;11:e045375. [PMID: 33827840 DOI: 10.1136/bmjopen-2020-045375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
47 Swerdlow DI, Rider DA, Yavari A, Lindholm MW, Campion GV, Nissen SE. Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics. Cardiovasc Res 2021:cvab100. [PMID: 33769464 DOI: 10.1093/cvr/cvab100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Wang D, Wang X, Wang L, Zhang J, Ma J, Xia G, Hong B. Antisense microRNA185 loaded liposome for efficient inhibition of the hepatic endogenous microRNA185 level. Eur J Pharm Sci 2021;161:105803. [PMID: 33722732 DOI: 10.1016/j.ejps.2021.105803] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Mert KU, Başaran Ö, Mert GÖ, Doğan V, Rencüzoğulları İ, Özlek B, Cinier G, Şenol U, Çelik O, Özlek E, Özdemir İH, Karadeniz FÖ, Bekar L, Aktaş M, Resulzade MM, Kalçık M, Aksan G, Akay K, Pekel N, Biteker M, Kayıkçıoğlu M. Management of LDL-cholesterol levels in patients with Diabetes Mellitus in Cardiology Practice: Real-life evidence of Under-treatment from the EPHESUS registry. Eur J Clin Invest 2021;51:e13528. [PMID: 33630348 DOI: 10.1111/eci.13528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
50 Tarn DM, Pletcher MJ, Tosqui R, Fernandez A, Tseng CH, Moriconi R, Bell DS, Barrientos M, Turner JA, Schwartz JB. Primary nonadherence to statin medications: Survey of patient perspectives. Prev Med Rep 2021;22:101357. [PMID: 33842201 DOI: 10.1016/j.pmedr.2021.101357] [Reference Citation Analysis]
51 Guadamuz JS, Durazo-Arvizu RA, Daviglus ML, Calip GS, Nutescu EA, Qato DM. Statin nonadherence in Latino and noncitizen neighborhoods in New York City, Los Angeles, and Chicago, 2012-2016. J Am Pharm Assoc (2003) 2021;61:e263-78. [PMID: 33637436 DOI: 10.1016/j.japh.2021.01.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Anantha-Narayanan M, Doshi RP, Patel K, Sheikh AB, Llanos-Chea F, Abbott JD, Shishehbor MH, Guzman RJ, Hiatt WR, Duval S, Mena-Hurtado C, Smolderen KG. Contemporary Trends in Hospital Admissions and Outcomes in Patients With Critical Limb Ischemia: An Analysis From the National Inpatient Sample Database. Circ Cardiovasc Qual Outcomes. 2021;14:e007539. [PMID: 33541110 DOI: 10.1161/circoutcomes.120.007539] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
53 Mahtta D, Lee MT, Ramsey DJ, Akeroyd JM, Krittanawong C, Khan SU, Sinh P, Alam M, Garratt KN, Schofield RS, Ballantyne CM, Petersen LA, Virani SS. Significant Facility-Level Variation in Utilization of and Adherence with Secondary Prevention Therapies Among Patients with Premature Atherosclerotic Cardiovascular Disease: Insights from the VITAL (Veterans wIth premaTure AtheroscLerosis) Registry7. Cardiovasc Drugs Ther 2021. [PMID: 33400053 DOI: 10.1007/s10557-020-07125-3] [Reference Citation Analysis]
54 Skladany L, Vnencakova J, Laffers L, Skvarkova B, Hrubá E, Molcan P, Koller T. Adherence to Oral Nutritional Supplements After Being Discharged from the Hospital is Low but Improves Outcome in Patients with Advanced Chronic Liver Disease. Patient Prefer Adherence 2020;14:2559-72. [PMID: 33447017 DOI: 10.2147/PPA.S283034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Kosmas CE, Skavdis A, Sourlas A, Papakonstantinou EJ, Peña Genao E, Echavarria Uceta R, Guzman E. Safety and Tolerability of PCSK9 Inhibitors: Current Insights. Clin Pharmacol 2020;12:191-202. [PMID: 33335431 DOI: 10.2147/CPAA.S288831] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Capranzano P, Francaviglia B, Sardone A, Agnello F, Valenti N, Frazzetto M, Legnazzi M, Occhipinti G, Scalia L, Calvi V, Capodanno D, Tamburino C. Suitability for elderly with heart disease of a QR code-based feedback of drug intake: Overcoming limitations of current medication adherence telemonitoring systems. Int J Cardiol 2021;327:209-16. [PMID: 33309634 DOI: 10.1016/j.ijcard.2020.12.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 An J, Zhang Y, Muntner P, Moran AE, Hsu JW, Reynolds K. Recurrent Atherosclerotic Cardiovascular Event Rates Differ Among Patients Meeting the Very High Risk Definition According to Age, Sex, Race/Ethnicity, and Socioeconomic Status. J Am Heart Assoc 2020;9:e017310. [PMID: 33222592 DOI: 10.1161/JAHA.120.017310] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
58 Ros-Castelló V, Natera-Villalba E, Gómez-López A, Sánchez-Sánchez A, Chico-García JL, García-Madrona S, Vera-Lechuga R, Matute-Lozano C, de Felipe Mimbrera A, Cruz-Culebras A, Alonso-Canovas A, Masjuan J. Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients. Cerebrovasc Dis Extra 2020;10:166-73. [PMID: 33176324 DOI: 10.1159/000511064] [Reference Citation Analysis]
59 Yao X, Shah ND, Gersh BJ, Lopez-Jimenez F, Noseworthy PA. Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016. JAMA Netw Open 2020;3:e2025505. [PMID: 33216139 DOI: 10.1001/jamanetworkopen.2020.25505] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
60 Lee YR, Oh SS, Jang S, Park E. Statin adherence and risk of all-cause, cancer, and cardiovascular mortality among dyslipidemia patients: A time-dependent analysis. Nutrition, Metabolism and Cardiovascular Diseases 2020;30:2207-14. [DOI: 10.1016/j.numecd.2020.07.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Cykert S, Keyserling TC, Pignone M, DeWalt D, Weiner BJ, Trogdon JG, Wroth T, Halladay J, Mackey M, Fine J, In Kim J, Cene C. A controlled trial of dissemination and implementation of a cardiovascular risk reduction strategy in small primary care practices. Health Serv Res 2020;55:944-53. [PMID: 33047340 DOI: 10.1111/1475-6773.13571] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
62 Ödesjö H, Björck S, Franzén S, Hjerpe P, Manhem K, Rosengren A, Thorn J, Adamsson Eryd S. Adherence to lipid-lowering guidelines for secondary prevention and potential reduction in CVD events in Swedish primary care: a cross-sectional study. BMJ Open 2020;10:e036920. [PMID: 33039993 DOI: 10.1136/bmjopen-2020-036920] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Owsiany MT, Hawley CE, Paik JM. Differential Diagnoses and Clinical Implications of Medication Nonadherence in Older Patients with Chronic Kidney Disease: A Review. Drugs Aging 2020;37:875-84. [PMID: 33030671 DOI: 10.1007/s40266-020-00804-8] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
64 Katzmann JL, Sorio-vilela F, Dornstauder E, Fraas U, Smieszek T, Zappacosta S, Laufs U. Non-statin lipid-lowering therapy over time in very-high-risk patients: effectiveness of fixed-dose statin/ezetimibe compared to separate pill combination on LDL-C. Clin Res Cardiol. [DOI: 10.1007/s00392-020-01740-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
65 Pang J, Chan DC, Watts GF. The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia. Curr Atheroscler Rep 2020;22:64. [PMID: 32870376 DOI: 10.1007/s11883-020-00884-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
66 Lin CP, Tung YC, Hsiao FC, Yang CH, Kao YW, Lin YS, Chu YC, Chu PH. Fixed-dose combination of amlodipine and atorvastatin improves clinical outcomes in patients with concomitant hypertension and dyslipidemia. J Clin Hypertens (Greenwich) 2020;22:1846-53. [PMID: 32862551 DOI: 10.1111/jch.14016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Mahtta D, Ahmed ST, Ramsey DJ, Akeroyd JM, Lee MT, Rodriguez F, Michos ED, Itchhaporia D, Nasir K, Alam M, Jneid H, Ballantyne CM, Petersen LA, Virani SS. Statin Prescription Rates, Adherence, and Associated Clinical Outcomes Among Women with PAD and ICVD. Cardiovasc Drugs Ther 2020;34:745-54. [PMID: 32840709 DOI: 10.1007/s10557-020-07057-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Jones NM, Mukamel DB, Malik S, Greenfield RS, Reikes A, Wong ND, Chow E. The costs outweigh the benefits: seeing side-effects online may decrease adherence to statins. BMC Med Inform Decis Mak 2020;20:197. [PMID: 32819361 DOI: 10.1186/s12911-020-01207-w] [Reference Citation Analysis]
69 Piña IL, Di Palo KE, Brown MT, Choudhry NK, Cvengros J, Whalen D, Whitsel LP, Johnson J. Medication adherence: Importance, issues and policy: A policy statement from the American Heart Association. Prog Cardiovasc Dis 2021;64:111-20. [PMID: 32800791 DOI: 10.1016/j.pcad.2020.08.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Mahtta D, Ramsey DJ, Al Rifai M, Nasir K, Samad Z, Aguilar D, Jneid H, Ballantyne CM, Petersen LA, Virani SS. Evaluation of Aspirin and Statin Therapy Use and Adherence in Patients With Premature Atherosclerotic Cardiovascular Disease. JAMA Netw Open 2020;3:e2011051. [PMID: 32816031 DOI: 10.1001/jamanetworkopen.2020.11051] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
71 Chen PY, Liu YH, Duan CY, Fan HL, Zeng LH, Guo W, Jiang L, Wei XB, He WF, Tao S, Guo ZQ, Chen JY, Tan N, He PC. Association of in-hospital intensive statins dosage and death in arteriosclerotic cardiovascular disease with percutaneous coronary intervention: insights of multicentre cohort from China. Eur J Clin Pharmacol 2020;76:1755-63. [PMID: 32700000 DOI: 10.1007/s00228-020-02966-1] [Reference Citation Analysis]
72 Ray KK, Stoekenbroek RM, Kallend D, Nishikido T, Leiter LA, Landmesser U, Wright RS, Wijngaard PLJ, Kastelein JJP. Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial. JAMA Cardiol 2019;4:1067-75. [PMID: 31553410 DOI: 10.1001/jamacardio.2019.3502] [Cited by in Crossref: 47] [Cited by in F6Publishing: 32] [Article Influence: 23.5] [Reference Citation Analysis]
73 Zeitouni M, Sabouret P, Kerneis M, Silvain J, Collet JP, Bruckert E, Montalescot G. 2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations. Eur Heart J Cardiovasc Pharmacother 2021;7:324-33. [PMID: 32652000 DOI: 10.1093/ehjcvp/pvaa077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
74 Tokgözoglu L, Zamorano JL. Current perspectives on the use of statins in the treatment of dyslipidaemic patients: focus on pitavastatin. Drugs Context 2020;9:2020-4-4. [PMID: 32587627 DOI: 10.7573/dic.2020-4-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Rezende Macedo do Nascimento RC, Mueller T, Godman B, MacBride Stewart S, Hurding S, de Assis Acurcio F, Guerra Junior AA, Alvares Teodoro J, Morton A, Bennie M, Kurdi A. Real-world evaluation of the impact of statin intensity on adherence and persistence to therapy: A Scottish population-based study. Br J Clin Pharmacol 2020;86:2349-61. [PMID: 32353163 DOI: 10.1111/bcp.14333] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
76 Romanelli RJ, Ito MK, Karalis DG, Huang HC, Iorga ŞR, Kam IW, Thompson S, Azar KMJ. Statin utilization and low-density lipoprotein cholesterol in statin-treated patients with atherosclerotic cardiovascular disease: Trends from a community-based health care delivery system, 2002-2016. J Clin Lipidol 2020;14:305-14. [PMID: 32362513 DOI: 10.1016/j.jacl.2020.03.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
77 Rymer JA, Mues KE, Monda KL, Bratton EW, Wirtz HS, Okerson T, Overman RA, Brookhart MA, Muntner P, Wang TY. Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation. J Am Heart Assoc 2020;9:e014347. [PMID: 32326795 DOI: 10.1161/JAHA.119.014347] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
78 Shiffman D, Louie JZ, Devlin JJ, Knowles JW, McPhaul MJ. Gaps in Dyslipidemia Care Among Working-Aged Individuals With Employer-Sponsored Health Care. J Am Heart Assoc 2020;9:e015807. [PMID: 32319337 DOI: 10.1161/JAHA.119.015807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
79 Nishimura S, Kumamaru H, Shoji S, Sawano M, Kohsaka S, Miyata H. Adherence to antihypertensive medication and its predictors among non-elderly adults in Japan. Hypertens Res 2020;43:705-14. [DOI: 10.1038/s41440-020-0440-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
80 Stock J. Targeting LDL cholesterol: Early treatment is key to population health. Atherosclerosis 2020;300:37-8. [PMID: 32253009 DOI: 10.1016/j.atherosclerosis.2020.03.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
81 Jia X, Ramsey DJ, Rifai MA, Ahmed ST, Akeroyd JM, Dixon DL, Gluckman TJ, Nambi V, Ballantyne CM, Petersen LA, Stone NJ, Virani SS. Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). Am J Cardiol 2020;125:874-9. [PMID: 31952841 DOI: 10.1016/j.amjcard.2019.12.030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
82 Ahmed ST, Mahtta D, Rehman H, Akeroyd J, Al Rifai M, Rodriguez F, Jneid H, Nasir K, Samad Z, Alam M, Petersen LA, Virani SS. Association between frequency of primary care provider visits and evidence-based statin prescribing and statin adherence: Findings from the Veterans Affairs system. Am Heart J 2020;221:9-18. [PMID: 31896038 DOI: 10.1016/j.ahj.2019.11.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
83 Khalaf K, Johnell K, Austin PC, Tyden P, Midlöv P, Perez-Vicente R, Merlo J. Low adherence to statin treatment during the 1st year after an acute myocardial infarction is associated with increased 2nd-year mortality risk-an inverse probability of treatment weighted study on 54 872 patients. Eur Heart J Cardiovasc Pharmacother 2021;7:141-7. [PMID: 32058542 DOI: 10.1093/ehjcvp/pvaa010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
84 Wang SW, Li LC, Su CH, Yang YH, Hsu TW, Hsu CN. Association of Statin and Its Lipophilicity With Cardiovascular Events in Patients Receiving Chronic Dialysis. Clin Pharmacol Ther 2020;107:1312-24. [PMID: 31715017 DOI: 10.1002/cpt.1722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
85 Mahla RS. Statin Use Recommendation in Cardiovascular Risk Management Is Controversial. Am J Med 2019;132:e862. [PMID: 31839121 DOI: 10.1016/j.amjmed.2019.03.011] [Reference Citation Analysis]
86 Zongo A, Simpson S, Johnson JA, Eurich DT. Change in Trajectories of Adherence to Lipid-Lowering Drugs Following Non-Fatal Acute Coronary Syndrome or Stroke. J Am Heart Assoc 2019;8:e013857. [PMID: 31771443 DOI: 10.1161/JAHA.119.013857] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Stone NJ, Grundy SM. The 2018 AHA/ACC/Multi-Society Cholesterol guidelines: Looking at past, present and future. Prog Cardiovasc Dis 2019;62:375-83. [PMID: 31733217 DOI: 10.1016/j.pcad.2019.11.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
88 Rehman H, Ahmed ST, Akeroyd J, Mahtta D, Jia X, Rifai MA, Nasir K, Jneid H, Khalid MU, Alam M, Toth PP, Virani SS. Relation Between Cardiology Follow-Up Visits, Evidence-Based Statin Prescribing, and Statin Adherence (from the Veterans Affairs Health Care System). Am J Cardiol 2019;124:1165-70. [PMID: 31405545 DOI: 10.1016/j.amjcard.2019.07.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
89 Toth PP, Granowitz C, Hull M, Anderson A, Philip S. Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis. Lipids Health Dis 2019;18:175. [PMID: 31526399 DOI: 10.1186/s12944-019-1099-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
90 Kuehne F, Jahn B, Conrads-Frank A, Bundo M, Arvandi M, Endel F, Popper N, Endel G, Urach C, Gyimesi M, Murray EJ, Danaei G, Gaziano TA, Pandya A, Siebert U. Guidance for a causal comparative effectiveness analysis emulating a target trial based on big real world evidence: when to start statin treatment. J Comp Eff Res 2019;8:1013-25. [PMID: 31512926 DOI: 10.2217/cer-2018-0103] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
91 Jia X, Al Rifai M, Ramsey DJ, Ahmed ST, Akeroyd JM, Nambi V, Ballantyne CM, Petersen LA, Stone NJ, Virani SS. Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System. Am J Med 2019;132:e693-700. [PMID: 31103643 DOI: 10.1016/j.amjmed.2019.04.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
92 Qamar A, Libby P. Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go? Curr Cardiol Rep 2019;21:77. [PMID: 31250329 DOI: 10.1007/s11886-019-1160-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
93 Phan DQ, Duan L, Lam B, Hekimian A, Wee D, Zadegan R, Lee MS. Statin Adherence and Mortality in Patients Aged 80 Years and Older After Acute Myocardial Infarction. J Am Geriatr Soc 2019;67:2045-9. [PMID: 31206603 DOI: 10.1111/jgs.16037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
94 Wierzbicki AS. Treating lipids in secondary prevention in a developing country: Lies, damn lies and the internet. Int J Clin Pract 2019;73:1-3. [PMID: 31168908 DOI: 10.1111/ijcp.13381] [Reference Citation Analysis]
95 Ruscica M, Reiner Z, Sirtori CR. Can we further optimize statin therapy to increase tolerability? Expert Opinion on Drug Discovery 2019;14:843-7. [DOI: 10.1080/17460441.2019.1615436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]